Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense® HER2 nanoparticle formulation under Good Manufacturing Practice (GMP) conditions has proceeded uninterrupted by the pandemic and has been completed on time. The second phase of manufacturing the nanoparticle material is expected to continue on schedule as the Company makes ready for its first human study.
[Video] Shareholder Webinar Recording | August 15, 2024
August 22, 2024
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation